Analysis indicates viability of research pathway for MDMA-assisted therapy to treat symptoms associated with traumatic brain injury CHICAGO and TORONTO, Dec. 14, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, is pleased to announce receipt of a commercial viability analysis conducted by the Boston…


Previous articleatai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
Next articlePT277 – Ryan Zurrer – Venture Capital, Reciprocity, and the Regenerative Financing Vine